Cite
HARVARD Citation
van Vollenhoven, R. et al. (n.d.). THU0151 Effects of tofacitinib (CP-690, 550), an oral janus kinase inhibitor, or adalimumab on patient reported outcomes in a phase 3 study of active rheumatoid arthritis. Annals of the rheumatic diseases. p. 206. [Online].